Cost-effectiveness analysis shows that early invasive strategies are best for the treatment of unstable angina and non-ST segment elevated myocardial infarction (MI), according to a report in the Oct. 16 issue of The Journal of the American Medical Association.
“Overall, we found the cost-effectiveness of the invasive strategy ranging from $8,371 to $25,538 per year of life gained, estimates that are favorable compared to other treatments used in current medical practice,” lead author Elizabeth Mahoney, PhD, from the Emory University School of Medicine in Atlanta, Georgia, says in a news release.
“Now we have evidence that early, aggressive and initially more expensive treatment of these patients is actually very cost-effective over time. This is good news for these patients and their physicians because aggressive treatment offers the best prognosis.”
Using economic data from 1,722 patients enrolled in the landmark Treatment Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS-TIMI 18) study, Mahoney’s group examined the initial hospitalization and six-month follow-up costs associated with acute coronary syndromes. Early invasive strategy consisted of routine catheterization and revascularization as indicated, whereas conservative management consisted of catheterization performed only for recurrent ischemia or positive stress test.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!